Literature DB >> 6861260

Interactions of human leukocyte interferon with vinca alkaloids and other chemotherapeutic agents against human tumors in clonogenic assay.

M S Aapro, D S Alberts, S E Salmon.   

Abstract

Purified human leukocyte interferon produced by recombinant techniques (IFN-alpha A) was tested in vitro with chemotherapeutic drugs, vinblastine (VLB), vincristine (VCR), vindesine (VDS), vinzolidine (VZL), cis-platinum (PLAT), doxorubicin (DOXO), etoposide (VP-16), and melphalan (MEL). The activity of these agents alone or in combination was tested against various human tumor cell lines, using a modified soft agar clonogenic assay. Three human tumor cell lines (myeloma, RPMI 8226; breast, MCF-7; and colon, WiDR) showed sensitivity to these agents at clinically achievable drug concentrations. Statistically significant synergistic activity against in vitro colony formation was observed with the combination of VLB and IFN-alpha A. An additive or sub-additive effect was usually observed with the other agents tested. Continuous exposure of the 8226 myeloma cell line to both IFN-alpha A and PLAT showed evidence of a more significant potentiation. It is hypothesized that the synergistic effect observed between VLB and IFN-alpha A is due to some of their common mechanisms of action.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6861260     DOI: 10.1007/bf00255753

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  35 in total

1.  Synergistic interaction of anticancer agents: a cellular perspective.

Authors:  F Valeriote; H s Lin
Journal:  Cancer Chemother Rep       Date:  1975 Sep-Oct

2.  Interaction of drugs with microtubule proteins.

Authors:  L Wilson; J R Bamburg; S B Mizel; L M Grisham; K M Creswell
Journal:  Fed Proc       Date:  1974-02

3.  Purification and characterization of recombinant human leukocyte interferon (IFLrA) with monoclonal antibodies.

Authors:  T Staehelin; D S Hobbs; H Kung; C Y Lai; S Pestka
Journal:  J Biol Chem       Date:  1981-09-25       Impact factor: 5.157

4.  Efficacy of combined interferon cyclophosphamide therapy after diagnosis of lymphoma in AKR mice.

Authors:  I Gresser; C Maury; M Tovey
Journal:  Eur J Cancer       Date:  1978-01       Impact factor: 9.162

5.  Pharmacologic studies of anticancer drugs with the human tumor stem cell assay.

Authors:  D S Alberts; S E Salmon; H S Chen; T E Moon; L Young; E A Surwit
Journal:  Cancer Chemother Pharmacol       Date:  1981       Impact factor: 3.333

6.  Sensitivity of human ovarian carcinoma cells to interferon and other antitumor agents as assessed by an in vitro semi-solid agar technique.

Authors:  L B Epstein; J T Shen; J S Abele; C C Reese
Journal:  Ann N Y Acad Sci       Date:  1980       Impact factor: 5.691

7.  Effect of fibroblast, lymphoid, and myeloid interferons on human tumor colony formation in vitro.

Authors:  E C Bradley; F W Ruscetti
Journal:  Cancer Res       Date:  1981-01       Impact factor: 12.701

8.  Retinoic acid: enhancement of a tumor and inhibition of interferon's antitumor action.

Authors:  S Baron; K M Kleyn; J K Russell; J E Blalock
Journal:  J Natl Cancer Inst       Date:  1981-07       Impact factor: 13.506

9.  Recombinant leukocyte A interferon: pharmacokinetics, single-dose tolerance, and biologic effects in cancer patients.

Authors:  J U Gutterman; S Fine; J Quesada; S J Horning; J F Levine; R Alexanian; L Bernhardt; M Kramer; H Spiegel; W Colburn; P Trown; T Merigan; Z Dziewanowski
Journal:  Ann Intern Med       Date:  1982-05       Impact factor: 25.391

10.  Human leukocyte interferon produced by E. coli is biologically active.

Authors:  D V Goeddel; E Yelverton; A Ullrich; H L Heyneker; G Miozzari; W Holmes; P H Seeburg; T Dull; L May; N Stebbing; R Crea; S Maeda; R McCandliss; A Sloma; J M Tabor; M Gross; P C Familletti; S Pestka
Journal:  Nature       Date:  1980-10-02       Impact factor: 49.962

View more
  26 in total

1.  Betulinic acid a radiosensitizer in head and neck squamous cell carcinoma cell lines.

Authors:  Christina Eder-Czembirek; Boban M Erovic; Cornelia Czembirek; Markus Brunner; Edgar Selzer; Richard Pötter; Dietmar Thurnher
Journal:  Strahlenther Onkol       Date:  2010-02-22       Impact factor: 3.621

Review 2.  Interferons: current status and future directions of this prototypic biological.

Authors:  R V Smalley; E C Borden
Journal:  Springer Semin Immunopathol       Date:  1986

3.  A phase II trial investigating primary immunochemotherapy for malignant pleural mesothelioma and the feasibility of adjuvant immunochemotherapy after maximal cytoreduction.

Authors:  H W Pass; B K Temeck; K Kranda; S M Steinberg; H I Pass
Journal:  Ann Surg Oncol       Date:  1995-05       Impact factor: 5.344

Review 4.  Alpha interferon: a look to the future.

Authors:  E M Bonnem
Journal:  Invest New Drugs       Date:  1987       Impact factor: 3.850

5.  Combining interferon with cytotoxic chemotherapy in patients with advanced breast cancer.

Authors:  R Ashford; T Priestman; T Mott; J M Bottomley
Journal:  Cancer Immunol Immunother       Date:  1986       Impact factor: 6.968

6.  The cyclooxygenase-2 inhibitor nimesulide, a nonsteroidal analgesic, decreases the effect of radiation therapy in head-and-neck cancer cells.

Authors:  Cornelia Czembirek; Christina Eder-Czembirek; Boban M Erovic; Dritan Turhani; Andreas Spittler; Edgar Selzer; Richard Pötter; Dietmar Thurnher
Journal:  Strahlenther Onkol       Date:  2009-05-15       Impact factor: 3.621

7.  Phase I study of escalating dose mitoxantrone in combination with alpha-2-interferon in patients with advanced solid tumors.

Authors:  G Gasparini; S Dal Fior; F Pozza; G A Panizzoni; S Favretto; D D Von Hoff
Journal:  Invest New Drugs       Date:  1991-08       Impact factor: 3.850

8.  The effects of taurolidine alone and in combination with doxorubicin or carboplatin in canine osteosarcoma in vitro.

Authors:  Kevin Marley; Stuart C Helfand; Wade A Edris; John E Mata; Alix I Gitelman; Jan Medlock; Bernard Séguin
Journal:  BMC Vet Res       Date:  2013-01-18       Impact factor: 2.741

9.  Ifosfamide, vindesine and recombinant alpha-interferon combination chemotherapy for metastatic renal cell carcinoma.

Authors:  H J König; W Gutmann; J Weissmüller
Journal:  J Cancer Res Clin Oncol       Date:  1991       Impact factor: 4.553

10.  Pharmacokinetics of epirubicin in man. Non-influence of alpha interferon.

Authors:  S Eksborg; K Mattson
Journal:  Med Oncol Tumor Pharmacother       Date:  1988
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.